Treatment options for early breast cancer in elderly women

Expert Review of Anticancer Therapy

Volumn 4, Issue 2, 2004, Pages 197-211

  Basso, Umberto ^a   Brunello, Antonella ^a   Pogliani, Claudia ^a   Monfardini, Silvio ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Adjuvant; Breast cancer; Chemotherapy; Elderly; Tamoxifen

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FULVESTRANT; METHOTREXATE; RALOXIFENE; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; AGED; ANEMIA; BLOOD TOXICITY; BREAST CANCER; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURGERY; CHEMOPROPHYLAXIS; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITION; COMORBIDITY; CONGESTIVE HEART FAILURE; CONSERVATIVE TREATMENT; DEHYDRATION; DRUG EFFICACY; DRUG FATALITY; EARLY CANCER; FEMALE; GERIATRICS; HORMONAL THERAPY; HUMAN; LIFE EXPECTANCY; MEDICAL DECISION MAKING; MUCOSA INFLAMMATION; NEUTROPENIA; OSTEOPOROSIS; PROGNOSIS; REVIEW; SIDE EFFECT;

EID: 1842790409     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.2.197     Document Type: Review

References (82)

1. Franceschi S, La Vecchia C. Cancer epidemiology in the elderly. Crit. Rev. Oncol. Hematol. 39, 219-226 (2001).
2. Levi F, Lucchini F, Negri E, Boyle P, La Vecchia C. Changed trends of cancer mortality in the elderly. Ann. Oncol. 12, 1467-1477 (2001).
3. Extermann M, Balducci L, Lyman GH. What threshold for adjuvant therapy in older breast cancer patients? J. Clin. Oncol. 18, 1709-1717 (2000).
4. Zappa M, Visioli CB, Ciatto S. Mammography screening in elderly women: Efficacy and cost-effectiveness. Crit. Rev. Oncol. Haematol. 46, 235-239 (2003).
5. Randolph WM, Goodwin JS, Mahnken JD, Freeman JL. Regular mammography use is associated with elimination of age-related disparities in size and stage of breast cancer at diagnosis. Ann. Intern. Med. 137, 783-790 (2002).
6. Mandelblatt J, Saba S, Teutsch S et al. The cost-effectiveness of screening mammography beyond age 65 years: A systematic review for the US Preventive Services Task Force. Ann. Intern. Med. 139, 835-842 (2003).
7. Boer R, de Koning HJ, Van der Maas PJ. A longer breast carcinoma screening interval for women of age older than 65 years? Cancer 86, 1506-1510 (1999).
8. Satariano WM. Comorbidity and functional status in older women with breast cancer: Implications for screening, treatment and prognosis. J. Gerontol. 47, 24-31 (1992).
9. Balducci L. Geriatric Oncology. Crit. Rev. Oncol. Hematol. 46, 211-220 (2003).
10. Cuzick J, Powles T, Veronesi U et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 361, 296-300 (2003).
11. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 351, 1451-1467 (1998).
12. Diab G, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J. Natl Cancer Inst. 92, 550-556 (2000).
13. Vlastos G, Mirza NQ, Meric F et al. Breast conservation therapy as a treatment option for the elderly. Cancer 92, 1092-1100 (2001).
14. Bouchardy C, Rapiti E, Gerald F et al. Undertreatment strongly decreases prognosis of breast cancer in elderly women. J. Clin. Oncol. 21, 3580-3587 (2003).
15. Daidone MG, Coradini D, Martelli G, Veneroni S. Primary breast cancer in elderly women: Biological profile and relation with clinical outcome. Crit. Rev. Oncol. Hematol. 45, 313-325 (2003).
16. Hurria A, Leung D, Trainor K, Borgen P, Norton L, Hudis C. Factors influencing treatment patterns of breast cancer patients age 75 and older. Crit. Rev. Oncol. Hematol. 46, 121-126 (2003).
17. Woodard S, Nadella PC, Kotur L, Wilson J, Burak WE, Shapiro CL. Older women with breast carcinoma are less likely to receive adjuvant chemotherapy. Cancer 98, 1141-1149 (2003).
18. Curigliano G, Gennari R, Rotmensz N et al. Breast cancer in elderly women: Features of disease presentation and choice of adjuvant therapies compared with younger postmenopausal patients. Proc. Am. Soc. Clin. Oncol. 22, 762 (2003).
19. Brunello A, Rossi E, Pogliani C et al. Limited use of adjuvant chemotherapy in elderly women with early breast cancer in the common practice: A retrospective analysis of 171 patients. Int. Soc. Geriatr. Oncol. (2003) (Abstract 55).
20. Balducci L, Extermann M, Carreca I. Management of breast cancer in the older woman. Cancer Control 8, 431-441 (2001).
21. Goldhirsch A, Wood C, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: Updated International Expert Consensus on the primary therapy of early breast cancer. J. Clin. Oncol. 21, 3357-3365 (2003).
22. DeMichele A, Putt M, Whang Y, Glick JH, Norman S. Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast carcinoma. Cancer 97, 2150-2159 (2003).
23. Holmes FF. Clinical course of cancer in the elderly. Cancer Control 1, 108-114 (1994).
24. Knoop AS, Bentzen SM, Nielsen MM, Rasmussen BB, Rose C. Value of epidermal growth factor receptor, HER-2, p53 and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J. Clin. Oncol. 19, 3376-3384 (2001).
25. Lipton A, Ali SM, Leitzel K et al. Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J. Clin. Oncol. 20, 1467-1472 (2002).
26. Moliterni A, Menard S, Valagussa P et al. HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer. J. Clin. Oncol. 21, 458-462 (2003).
27. Monfardini S, Balducci L. A comprehensive geriatric assessment (CGA) is necessary for the study and the management of cancer in the elderly. Eur. J. Cancer 35, 1771-1772 (1999).
28. Repetto L, Fratino L, Audisio RA et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: An Italian Group for Geriatric Oncology Study. J. Clin. Oncol. 20, 404-502 (2002).
29. Zagonel V, Fratino L, Piselli P et al. The comprehensive geriatric assessment (CGA) predicts mortality among elderly cancer patients (ECP). Proc. Am. Soc. Clin. Oncol. 21, 365a (2002).
30. Yancik R, Wesley MN, Ries LA et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285, 885-889 (2001).
31. Extermann M, Meyer J, McGinnis M et al. A comprehensive geriatric intervention detects multiple problems in older breast cancer patients. Crit. Rev. Oncol. Hematol. (2004) (In Press).
32. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies. Development and validation. J. Chron. Dis. 40, 373-383 (1987).
33. Extermann M. Measuring comorbidity in older cancer patients. Eur. J. Cancer 36, 453-471 (2000).
34. Monfardini S, Crivellari G, Zoli V et al. Vinorelbine (VNR) and prednisone (PDN) in elderly (70 years) frail patients (pts) with non-Hodgkin's lymphomas (NHL). A Phase II study of Non-Hodgkin's Lymphoma Co-operative Study Group (NHLCSG). Proc. Am. Soc. Clin. Oncol. 21, 204b (2002).
35. Bernardi D, Milan I, Balzarotti M et al. Comprehensive geriatric evaluation in elderly patients with lymphoma: Feasibility of a patient tailored treatment plan. J. Clin. Oncol. 21, 754-757 (2003).
36. Kemeny MM, Peterson BL, Kornblith AB et al. Barriers to clinical trial participation by older women with breast cancer. J. Clin. Oncol. 21, 2268-2275 (2003).
37. Lewis JH, Kilgore ML, Goldman DP et al. Participation of patients 65 years of age or older in cancer clinical trials. J. Clin. Oncol. 27, 1393-1389 (2003).
38. Mandelblatt JS, Edge SB, Meropol NJ et al. Predictors of long-term outcomes in older breast cancer survivors: Perceptions versus patterns of care. J. Clin. Oncol. 21, 855-863 (2003).
39. Ganz PA, Guadagnoli F, Landrum MB, Lash TL, Rakowski W, Silliman RA. Breast cancer in older women: Quality of life and psychosocial adjustment in the 15 months after diagnosis. J. Clin. Oncol. 21, 4027-4033 (2003).
40. Goodwin JS, Satish S, Anderson ET, Nattinger AB, Freeman JL. Effect of nurse case management on the treatment of older women with breast cancer. J. Am. Geriatr. Soc. 51, 1252-1259 (2003).
41. Earle CC, Burstein HJ, Winer EP, Weeks J. Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J. Clin. Oncol. 21, 1447-1451 (2003).
42. Bates T, Fennessy M, Riley DJ et al. Breast cancer in the elderly: Surgery improves survival. The results of a Cancer Research Campaign Trial. Proc. Am. Soc. Clin. Oncol. 20, 1533 (2001).
43. Fentiman JS, Christiaens MR, Paridaens R et al. Treatment of operable breast cancer in the elderly: A randomized clinical trial EORTC 10851 comparing TAM alone with modified radical mastectomy. Eur. J. Cancer 39, 309-316 (2003).
44. Mustacchi G, Ceccherini R, Milani S et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the Phase III randomized controlled multicenter GRETA trial. Ann. Oncol. 14, 414-420 (2003).
45. Warren JL, Brown ML, PìFay MP, Schussler N, Potosky AL, Riley GF. Costs of treatment for elderly women with early-stage breast cancer in fee-for-service settings. J. Clin. Oncol. 20, 307-316 (2003).
46. Keating NL, Landrum MB, Ayanian JZ, Winer EP, Guadagnoli E. Consultation with a medical oncologist before surgery and type of surgery among elderly women with early-stage breast cancer. J. Clin. Oncol. 21, 4532-4539 (2003).
47. Martelli G, Miceli R, De Palo G et al. Is axillary lymph node dissection necessary in elderly patients with breast carcinoma who have a clinically uninvolved axilla? Cancer 97, 1156-1163 (2003).
48. Truong PT, Bernstein V, Elaine W, Chua B, Speers C, Olivotto IA. Age-related variations in the use of axillary dissection: A survival analysis of 8038 women with T1-ST2 breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 54, 794-803 (2002).
49. Greco M, Gennaro M, Valagussa P et al. Impact of nodal status on indication for adjuvant treatment in clinically node negative breast cancer. Ann. Oncol. 11, 1137-1140 (2000).
50. Parmigiani G, Berry DA, Winer EP et al. Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis. J. Clin. Oncol. 17, 1465-1473 (1999).
51. Williams AF, Vadgama A, Franks PJ, Mortimer PS. A randomized controlled crossover study of manual lymphatic drainage therapy in women with breast cancer-related lymphoedema. Eur. J. Cancer Care (Engl.) 11, 254-261 (2002).
52. Szuba A, Achalu R, Rockson SG. Decongestive lymphatic therapy for patients with breast carcinoma-associated lymphoedema. A randomized, prospective study of a role for adjunctive intermittent pneumatic compression. Cancer 95, 2260-2267 (2002).
53. Carati CJ, Anderson SN, Gannon BJ, Piller NB. Treatment of postmastectomy lymphoedema with low-level laser therapy: A double-blind, placebo-controlled trial. Cancer 98, 1114-1122 (2003).
54. Veronesi U, Paganelli G, Viale G et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N. Engl. J. Med. 349, 546-553 (2003).
55. Olmi P, Fallai C, Cerrotta AM, Lozza L, Badii D. Breast cancer in the elderly: The role of adjuvant radiation therapy. Crit. Rev. Oncol. Haematol. 48, 165-178 (2003).
56. Hannoun-Levi JM, Courdi A, Marsiglia H et al. Breast cancer in elderly women: Is partial breast irradiation a good alternative? Breast Cancer Res. Treat. 81, 243-251 (2003).
57. Jobsen JJ, van der Palen J, Ong F, Meerwaldt JH. The value of a positive margin for invasive carcinoma in breast-conservative treatment in relation to local recurrence is limited to young women only. Int. J. Radiat. Oncol. Biol. Phys. 57, 724-731 (2003).
58. Vrieling C, Collette L, Fourquet A et al. Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients? Eur. J. Cancer 399, 32-44 (2003).
59. Punglia RS, Kuntz K, Lee JH, Recht A. Radiation therapy plus tamoxifen versus tamoxifen alone after breast conserving surgery in postmenopausal women with Stage I breast cancer: A decision analysis. J. Clin. Oncol. 21, 2260-2267 (2003).
60. Veronesi U, Gatti G, Luini A. Intraoperative radiation therapy for breast cancer: Technical notes. Breast 9, 106-112 (2003).
61. Baum M, Buzdar A, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98, 1802-1810 (2003).
62. Crivellari D, Price K, Gelber RD et al. Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group trial IV. J. Clin. Oncol. 21, 4517-4523 (2003).
63. Eifel P, Axelson JA, Costa J et al. National Institute of Health (NIH) Consensus Development Conference Statement. Adjuvant therapy for breast cancer, November 1-3, 2000. J. Natl Cancer Inst. 93, 978-989 (2001).
64. Blackman SB, Lash TL, Fink A, Ganz PA, Silliman RA. Advanced age and adjuvant tamoxifen prescription in early-stage breast carcinoma patients. Cancer 95, 2465-2472 (2002).
65. Monfardini S. Prescribing anticancer drugs in elderly cancer patients Eur. J. Cancer 38, 2341-2346 (2002).
66. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J. Clin. Oncol. 21, 602-606 (2003).
67. Early Breast Cancer Trialist's Collaborative Group. Poly-chemotherapy for early breast cancer: An overview of the randomized trials. Lancet 352, 930-942 (1998).
68. Biganzoli L, Goldhirsch A, Straehle C et al. Breast International Group (BIG) survey of medical oncologist attitudes to the management of elderly patients (pts) with early breast cancer (BC). Ann. Oncol. 13, 105s (2002).
69. Crivellari D, Bonetti M, Castiglione-Gertsch M. Burdens and benefits of adjuvant cyclophosphamide, methotrexate and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII. J. Clin. Oncol. 18, 1412-1422 (2000).
70. Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J. Clin. Oncol. 20, 4636-4642 (2002).
71. Gelman RS, Taylor SG. Cyclophosphamide, methotrexate and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: The elimination of age trends in toxicity by using doses based on creatinine clearance. J. Clin. Oncol. 2, 1404-1413 (1984).
72. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-positive breast cancer. The results of 20 years of follow-up. N. Engl. J. Med. 332, 901-906 (1995).
73. Colleoni M, Gelber S, Coates AS et al. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer J. Clin. Oncol. 19, 4141-44149 (2001).
74. Hartman AR, Fleming GF, Dillon JJ. Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer. Clin. Breast Cancer 2, 138-143 (2001).
75. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin. Cancer 97, 2869-2879 (2003).
76. Ibrahim NK, Buzdar AU, Asmar L, Theriault RL, Hortobagyi GN. Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: The MD Anderson experience with long-term follow-up. Ann. Oncol. 11, 1597-1601 (2000).
77. Dees EC, O'Reilly S, Goodman SN et al. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest. 18, 521-529 (2000).
78. Fargeot R, Roche H, Bonneterre JM et al. Disease-free survival (DFS) advantage of weekly epirubicin plus tamoxifen vs. tamoxifen (TAM) alone as adjuvant treatment of operable, node-positive (N+) elderly breast cancer (BC) patient (pts): 5 year follow-up results of French Adjuvant Study Group, FASG-08 Trial. Proc. Am. Soc. Clin. Oncol. 21, 37a (2002).
79. Liang W, Burnett CB, Rowland JH et al. Communication between physicians and older women with localized breast cancer: Implications for treatment and patient satisfaction. J. Clin. Oncol. 20, 1008-1016 (2002).
80. Extermann M, Albrand G, Chen H et al. Are older French patients as willing as older American patients to undertake chemotherapy? J. Clin. Oncol. 21, 3214-3219 (2003).
81. Monfardini S, Perrone F. Should adjuvant chemotherapy be used to treat breast cancer in elderly patients (≥70 years of age)? Eur. J. Cancer 33, 1723-1724 (1997).
82. Clarke R, Liu MC, Bouker KB et al. Anti-estrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22, 7316-7339 (2003).